Loading stock data…
OCUL
$9.43+0.06 (+0.64%)
Market ClosedLast close May 1
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Ocular Therapeutix, Inc. in the Healthcare sector is trading at $9.43. The stock is currently 43% below its 52-week high of $16.44, remaining 14.7% below its 200-day moving average. Technical signals show neutral RSI of 60 and bullish MACD crossover, explaining why OCUL maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 60) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$9.43
Potential Upside
5%
Whystock Fair Value$9.90
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus11 analysts
Mean target$26.00+175.7%
Range$18.00 – $34.00
Fundamentals
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.10B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.95
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-33.13%
Volume
Today's trading volume
2.29M
Recent News
How Investors Are Reacting To Ocular Therapeutix (OCUL) Advancing AXPAXLI Toward NDA After Positive SOL-1 Trial
Ocular Therapeutix, Inc. recently presented updates at Eyecelerator 2026 in Denver and is now in formal FDA discussions after its SOL-1 Phase 3 trial for AXPAXLI in wet age-related macular degeneration met its primary endpoint with strong statistical significance and a favorable safety profile. The company is preparing an NDA for AXPAXLI while planning independent commercialization backed by patent protection to 2044, scalable hydrogel manufacturing and the potential for a first-in-category...
How The SOL-1 Readout Is Reframing The Story For Ocular Therapeutix (OCUL)
Ocular Therapeutix’s latest update keeps the model fair value anchored at US$26.0 per share, signaling that core assumptions around Axpaxli and the broader pipeline are largely intact despite recent volatility. Analysts linking this steady fair value to the detailed SOL-1 Phase 3 readout point to a mix of optimism on approval odds and dosing profile, alongside tougher questions about how the therapy might stack up against Eylea in real world use. As you read on, you will see how to track this...
Ocular Therapeutix Inc. (OCUL) Appears Highly Attractive Following SOL-1 Clinical Trial Data
Ocular Therapeutix Inc. (NASDAQ:OCUL) is one of the 10 best biotech stocks with highest upside potential. On April 13, William Blair maintained an Outperform rating on Ocular Therapeutix (NASDAQ:OCUL) right after the presentation of additional SOL-1 clinical trial data. According to the firm, this post-hoc investigation unequivocally supports Axpaxli’s overall effectiveness and durability. In particular, […]
Ocular Therapeutix Says FDA Talks Progressing as It Eyes AXPAXLI NDA for Wet AMD on SOL-1 Data
Ocular Therapeutix (NASDAQ:OCUL) Executive Chairman, President, and CEO Dr. Pravin Dugel said the company is engaged in formal discussions with the U.S. Food and Drug Administration as it works toward a New Drug Application submission for AXPAXLI in wet age-related macular degeneration (wet AMD), wi
Ocular Therapeutix (OCUL) Announces Additional Positive Data From the SOL-1 Phase 3 Superiority Trial of AXPAXLI
Ocular Therapeutix Inc. (NASDAQ:OCUL) is one of the best low priced biotech stocks to invest in. Ocular Therapeutix Inc. (NASDAQ:OCUL) announced on April 13 additional positive Week 52 data from the SOL-1 Phase 3 superiority trial of AXPAXLI (also known as OTX-TKI), which is the company’s investigational product candidate for the treatment of wet age-related macular […]